Skip navigation
Please use this identifier to cite or link to this item:
Files in This Item:
File SizeFormat 
ARTIGO_RifapentineLatentTuberculosis.pdf427,25 kBAdobe PDFView/Open
Full metadata record
DC FieldValueLanguage
dc.contributor.authorVidal, Júlia Souzapt_BR
dc.contributor.authorSilva, Marcus Tolentinopt_BR
dc.contributor.authorSanchez, Mauro Niskierpt_BR
dc.identifier.citationVIDAL, Júlia Souza; SILVA, Marcus Tolentino; SANCHEZ, Mauro Niskier. Rifapentine for latent tuberculosis infection treatment in the general population and human immunodeficiency virus-positive patients: summary of evidence. Revista da Sociedade Brasileira de Medicina Tropical, Uberaba, v. 48, n. 5, p. 507-513, set./out. 2015. Disponível em: <>. Acesso em: 10 maio 2018. doi:
dc.publisherSociedade Brasileira de Medicina Tropical - SBMTpt_BR
dc.rightsAcesso Abertopt_BR
dc.titleRifapentine for latent tuberculosis infection treatment in the general population and human immunodeficiency virus-positive patients : summary of evidencept_BR
dc.subject.keywordProcesso decisóriopt_BR
dc.rights.licenseRevista da Sociedade Brasileira de Medicina Tropical - This is an Open Access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited (CC BY 4.0). Fonte: Acesso em: 10 maio 2018.-
dc.description.abstract1Latent tuberculosis infection (LTBI) and human immunodeficiency virus (HIV)-coinfection are challenges in the control of tuberculosis transmission. We aimed to assess and summarize evidence available in the literature regarding the treatment of LTBI in both the general and HIV-positive population, in order to support decision making by the Brazilian Tuberculosis Control Program for LTBI chemoprophylaxis. We searched MEDLINE, Cochrane Library, Centre for Reviews and Dissemination, Embase, LILACS, SciELO, Trip database, National Guideline Clearinghouse, and the Brazilian Theses Repository to identify systematic reviews, randomized clinical trials, clinical guidelines, evidence-based synopses, reports of health technology assessment agencies, and theses that investigated rifapentine and isoniazid combination compared to isoniazid monotherapy. We assessed the quality of evidence from randomized clinical trials using the Jadad Scale and recommendations from other evidence sources using the Grading of Recommendations, Assessment, Development, and Evaluations approach. The available evidence suggests that there are no differences between rifapentine + isoniazid short-course treatment and the standard 6-month isoniazid therapy in reducing active tuberculosis incidence or death. Adherence was better with directly observed rifapentine therapy compared to self-administered isoniazid. The quality of evidence obtained was moderate, and on the basis of this evidence, rifapentine is recommended by one guideline. Available evidence assessment considering the perspective of higher adherence rates, lower costs, and local peculiarity context might support rifapentine use for LTBI in the general or HIV-positive populations. Since novel trials are ongoing, further studies should include patients on antiretroviral therapy.-
Appears in Collections:DSC - Artigos publicados em periódicos e preprints

Show simple item record Recommend this item " class="statisticsLink btn btn-primary" href="/handle/10482/29527/statistics">

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.